Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Rizq O, et al. Among authors: mimura n. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10. Clin Cancer Res. 2017. PMID: 28490465 Free PMC article.
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y, Chiba T, Oshima M, Koide S, Rizq O, Aoyama K, Ao J, Kaneko T, Kanzaki H, Kanayama K, Maeda T, Saito T, Nakagawa R, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Nakamoto S, Yasui S, Mikata R, Muroyama R, Kanda T, Maruyama H, Kato J, Mimura N, Ma A, Jin J, Zen Y, Otsuka M, Kaneda A, Iwama A, Kato N. Kusakabe Y, et al. Among authors: mimura n. Sci Rep. 2021 Nov 1;11(1):21396. doi: 10.1038/s41598-021-00889-0. Sci Rep. 2021. PMID: 34725436 Free PMC article.
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Mimura N, et al. Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16. Cancer Res. 2014. PMID: 24934808 Free PMC article.
Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells.
Kanayama K, Chiba T, Oshima M, Kanzaki H, Koide S, Saraya A, Miyagi S, Mimura N, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Maruyama H, Iwama A, Kato N. Kanayama K, et al. Among authors: mimura n. Stem Cells Int. 2019 Apr 1;2019:9789240. doi: 10.1155/2019/9789240. eCollection 2019. Stem Cells Int. 2019. PMID: 31065285 Free PMC article.
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Zhong C, Kayamori K, Koide S, Shinoda D, Oshima M, Nakajima-Takagi Y, Nagai Y, Mimura N, Sakaida E, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Yamaguchi K, Furukawa Y, Lennox W, Sheedy J, Weetall M, Iwama A. Zhong C, et al. Among authors: mimura n. Cancer Sci. 2020 Dec;111(12):4336-4347. doi: 10.1111/cas.14684. Epub 2020 Nov 2. Cancer Sci. 2020. PMID: 33037737 Free PMC article.
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. Nagai Y, et al. Among authors: mimura n. Sci Rep. 2021 Jan 22;11(1):2074. doi: 10.1038/s41598-021-81577-x. Sci Rep. 2021. PMID: 33483574 Free PMC article.
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, Kuribayashi W, Oshima M, Nakajima-Takagi Y, Yamashita M, Mimura N, Becker HJ, Izawa K, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Lennox W, Sheedy J, Weetall M, Sakaida E, Yokote K, Iwama A. Kayamori K, et al. Among authors: mimura n. Blood Adv. 2021 Jan 26;5(2):438-450. doi: 10.1182/bloodadvances.2020001461. Blood Adv. 2021. PMID: 33496740 Free PMC article.
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M, Chiba T, Zen Y, Oshima M, Kusakabe Y, Noguchi Y, Yuki K, Koide S, Tara S, Saraya A, Aoyama K, Mimura N, Miyagi S, Inoue M, Wakamatsu T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Yokosuka O, Iwama A. Yokoyama M, et al. Among authors: mimura n. Oncotarget. 2017 Mar 28;8(13):21315-21326. doi: 10.18632/oncotarget.15528. Oncotarget. 2017. PMID: 28423509 Free PMC article.
Genetic and transcriptional landscape of plasma cells in POEMS syndrome.
Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, Aoyama K, Saraya A, Koide S, Rizq O, Hasegawa Y, Shiraishi Y, Chiba K, Tanaka H, Nishijima D, Isshiki Y, Kayamori K, Kawajiri-Manako C, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Miyano S, Ohara O, Yokote K, Sakaida E, Kuwabara S, Sanada M, Iwama A, Ogawa S, Nakaseko C. Nagao Y, et al. Among authors: mimura n. Leukemia. 2019 Jul;33(7):1723-1735. doi: 10.1038/s41375-018-0348-x. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635632
257 results